Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: pyrotinib combined with trastuzumab, dalpiciclib and letrozole
Sponsor: Yantai Yuhuangding Hospital
Collaborators: Jiangsu Hengrui Pharmaceutical Co., Ltd.